Sugi Predict

Sugi Predict / Compounds / SCHEMBL3144886

SCHEMBL3144886

SCHEMBL3144886

C/C(=N\O)c1cccc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ CTSL P07711 1/20 0.56
▸ PARP1 P09874 1/20 0.48
▸ GAA P10253 2/20 0.47
▸ CASP3 P42574 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ SENP6 Q9GZR1 1/20 0.46
▸ GRIN2B Q13224 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ FURIN P09958 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3144887 1.00 HTT (0.62) HTTKDM4EMEN1KMT2ASMN1; SMN2
Water SCHEMBL11591334 0.98 HTT (0.61) HTTKDM4EMEN1KMT2ASMN1; SMN2
Chlorobenzene SCHEMBL28114087 0.81 TSHR (0.48) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL6810853 0.79 KDM4E (0.57) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL4375606 0.78 PARP1 (0.56) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL7622154 0.78 KMT2A (0.47) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3096979 0.78 PARP1 (0.56) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL8661356 0.78 KMT2A (0.47) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL10813945 0.77 PARP1 (0.52) HTTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL10813941 0.77 PARP1 (0.52) HTTKDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927218-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2018-07-04 — — EP disclosed
US-9725423-B2 Tetrazolinone compound and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-08 — — US disclosed
US-20150299146-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-10-22 — — US disclosed
EP-2927218-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-10-07 — — EP disclosed
EP-2366704-B1 Inhibitors of serine proteases VERTEX PHARMA (US) 2013-10-23 — — EP disclosed
EP-1511742-B1 KINASE INHIBITORS CYTOPIA RES PTY LTD (AU) 2010-02-03 — — EP disclosed
US-7598272-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-10-06 — — US disclosed
US-7511047-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-03-31 — — US disclosed
EP-1513821-B1 PROTEIN KINASE INHIBITORS CYTOPIA PTY LTD (AU) 2007-10-31 — — EP disclosed
US-7259179-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-08-21 — — US disclosed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 — — US disclosed
US-20060270687-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-11-30 — — US disclosed
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-10-26 — — US disclosed
US-7122550-B2 Protein kinase inhibitors CYTOPIA PTY LTD (AU) 2006-10-17 — — US disclosed
US-20060148824-A1 Protein kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2006-07-06 — — US disclosed
EP-1511742-A1 KINASE INHIBITORS Cytopia PTY Ltd (AU) 2005-03-09 — — EP disclosed
US-20050004140-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2005-01-06 — — US disclosed
US-20040235862-A1 For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2004-11-25 — — US disclosed
WO-2003099811-A1 KINASE INHIBITORS CYTOPIA PTY LTD (AU) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235862-A1 For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer LCK, IRAK1, MAP2K5 HTT 4187/4885KDM4E 2692/4885MEN1 1677/4885
US-20060270687-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 HTT 2541/4885KDM4E 1738/4885MEN1 889/4885
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states MAP4K2, MAP4K5, MAP4K4 HTT 1397/4885KDM4E 1505/4885MEN1 753/4885
US-20050004140-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 HTT 2541/4885KDM4E 1738/4885MEN1 889/4885
US-20060148824-A1 Protein kinase inhibitors MAP3K20, MAP4K2, MAP3K1 HTT 3975/4885KDM4E 1981/4885MEN1 1877/4885
US-20070161635-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K10 HTT 2135/4885KDM4E 2364/4885MEN1 1251/4885
US-20150299146-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF RTN3, CYCS, ATL3 HTT 1492/4885KDM4E 2748/4885MEN1 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.